Search research articles
Contact Us
Filters
Showing results (21-30 of 60) with videos related to
Page
of 6
Sort By:
Nuclear Medicine and Biology
|
January 9, 2026
Rodent biodistribution and dosimetry of the PET radioligands [<sup>18</sup>F]CHDI-385 and [<sup>18</sup>F]CHDI-386 targeting mutant huntingtin aggregates
Jordy Akkermans, Alan Miranda, Jeroen Verhaeghe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 13, 2025
In Vivo PET Imaging of [<sup>18</sup>F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease
Franziska Zajicek, Filipe Elvas, Alan Miranda, et al.
Molecular Imaging and Biology
|
December 4, 2019
In vitro and In vivo Assessment of Suitable Reference Region and Kinetic Modelling for the mGluR1 Radioligand [<sup>11</sup>C]ITDM in Mice
Daniele Bertoglio, Jeroen Verhaeghe, Špela Korat, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 17, 2021
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem
Daniele Bertoglio, Jeroen Verhaeghe, Leonie Wyffels, et al.
Scientific Reports
|
June 23, 2023
Longitudinal investigation of changes in resting-state co-activation patterns and their predictive ability in the zQ175 DN mouse model of Huntington's disease
Mohit H Adhikari, Tamara Vasilkovska, Roger Cachope, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
May 16, 2022
Validation, kinetic modeling, and test-retest reproducibility of [<sup>18</sup>F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice
Daniele Bertoglio, Franziska Zajicek, Stef De Lombaerde, et al.
Journal of Medicinal Chemistry
|
February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives
Mark H Norman, Longbin Liu, Matthew Lee, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 27, 2024
Preclinical evaluation of the novel [<sup>18</sup>F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease
Franziska Zajicek, Jeroen Verhaeghe, Stef De Lombaerde, et al.
Molecular Neurobiology
|
January 9, 2020
Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study
Daniele Bertoglio, Jeroen Verhaeghe, Špela Korat, et al.
Neurobiology of Disease
|
March 24, 2023
Resting-state fMRI reveals longitudinal alterations in brain network connectivity in the zQ175DN mouse model of Huntington's disease
Tamara Vasilkovska, Mohit H Adhikari, Johan Van Audekerke, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 60) with videos related to
Sort By:
Page
of 6
Nuclear Medicine and Biology
|
January 9, 2026
Rodent biodistribution and dosimetry of the PET radioligands [<sup>18</sup>F]CHDI-385 and [<sup>18</sup>F]CHDI-386 targeting mutant huntingtin aggregates
Jordy Akkermans, Alan Miranda, Jeroen Verhaeghe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 13, 2025
In Vivo PET Imaging of [<sup>18</sup>F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease
Franziska Zajicek, Filipe Elvas, Alan Miranda, et al.
Molecular Imaging and Biology
|
December 4, 2019
In vitro and In vivo Assessment of Suitable Reference Region and Kinetic Modelling for the mGluR1 Radioligand [<sup>11</sup>C]ITDM in Mice
Daniele Bertoglio, Jeroen Verhaeghe, Špela Korat, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 17, 2021
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem
Daniele Bertoglio, Jeroen Verhaeghe, Leonie Wyffels, et al.
Scientific Reports
|
June 23, 2023
Longitudinal investigation of changes in resting-state co-activation patterns and their predictive ability in the zQ175 DN mouse model of Huntington's disease
Mohit H Adhikari, Tamara Vasilkovska, Roger Cachope, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
May 16, 2022
Validation, kinetic modeling, and test-retest reproducibility of [<sup>18</sup>F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice
Daniele Bertoglio, Franziska Zajicek, Stef De Lombaerde, et al.
Journal of Medicinal Chemistry
|
February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives
Mark H Norman, Longbin Liu, Matthew Lee, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 27, 2024
Preclinical evaluation of the novel [<sup>18</sup>F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease
Franziska Zajicek, Jeroen Verhaeghe, Stef De Lombaerde, et al.
Molecular Neurobiology
|
January 9, 2020
Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study
Daniele Bertoglio, Jeroen Verhaeghe, Špela Korat, et al.
Neurobiology of Disease
|
March 24, 2023
Resting-state fMRI reveals longitudinal alterations in brain network connectivity in the zQ175DN mouse model of Huntington's disease
Tamara Vasilkovska, Mohit H Adhikari, Johan Van Audekerke, et al.
Page
of 6